Heat Biologics, Inc.
(NASDAQ : HTBX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.15%247.721.3%$844.18m
MRNAModerna, Inc. 2.92%69.870.0%$763.28m
NVAXNovavax, Inc. -6.19%108.3696.5%$693.95m
IMMUImmunomedics, Inc. 0.22%85.5311.0%$600.97m
GILDGilead Sciences, Inc. 0.02%65.051.0%$599.14m
REGNRegeneron Pharmaceuticals, Inc. -1.73%555.242.7%$445.10m
BIIBBiogen, Inc. -0.32%274.481.6%$332.97m
VRTXVertex Pharmaceuticals, Inc. -2.24%265.391.9%$329.17m
ILMNIllumina, Inc. -0.85%295.503.5%$313.09m
SRNESorrento Therapeutics, Inc. -0.53%9.431.5%$274.82m
ALXNAlexion Pharmaceuticals, Inc. -0.36%113.722.0%$266.55m
BMRNBioMarin Pharmaceutical, Inc. 1.30%79.384.3%$239.49m
MNTAMomenta Pharmaceuticals, Inc. -0.13%52.263.0%$237.34m
VXRTVaxart, Inc. 3.01%8.220.0%$213.57m
SGENSeattle Genetics, Inc. 3.01%180.946.0%$194.15m

Company Profile

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.